Clinical importance of autoantibodies in lupus nephritis

References

• Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum.54, 2963–2969 (2006).
   PubMedGoogle Scholar
• Bastian HM, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus11, 152–160 (2002).
   PubMed Web of Science ®Google Scholar
• Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford)45, 1144–1147 (2006).
   PubMedGoogle Scholar
• Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int.51, 1188–1195 (1997).
   PubMed Web of Science ®Google Scholar
• Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol.15(2), 241–250 (2004). Erratum in: J. Am. Soc. Nephrol.15(3), 835–836 (2004).
   PubMed Web of Science ®Google Scholar
• Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: the end of an era? Lupus13, 1–3 (2004).
   PubMedGoogle Scholar
• Thomson KF, Murphy A, Goodfield MJ, Misbah SA. Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells? J. Clin. Pathol.54, 413 (2001).
   PubMedGoogle Scholar
• Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol. Dial. Transplant.19, 1420–1426 (2004).
   PubMedGoogle Scholar
• Markowitz GS, Schwimmer JA, Stokes MB et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int.64, 1232–1240 (2003).
   PubMedGoogle Scholar
• Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med.349, 1526–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford)46, 1052–1056 (2007).
   PubMed Web of Science ®Google Scholar
• Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus13, 290–297 (2004).
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum.33, 634–643 (1990).
   PubMed Web of Science ®Google Scholar
• Kavanaugh AF, Solomon DH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum.47, 546–555 (2002).
   PubMed Web of Science ®Google Scholar
• Fernando MM, Isenberg DA. How to monitor SLE in routine clinical practice. Ann. Rheum. Dis.64, 524–527 (2005).
   PubMed Web of Science ®Google Scholar
• Okamura M, Kanayama Y, Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann. Rheum. Dis.52, 14–20 (1993).
   PubMed Web of Science ®Google Scholar
• Amoura Z, Piette JC, Chabre H et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum.40, 2217–2225 (1997).
   PubMed Web of Science ®Google Scholar
• Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum.43, 2307–2315 (2000).
   PubMedGoogle Scholar
• Ghirardello A, Doria A, Zampieri S et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J. Autoimmun.22, 235–240 (2004).
   PubMedGoogle Scholar
• Suer W, Dahnrich C, Schlumberger W, Stocker W. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J. Autoimmun.22, 325–334 (2004).
   PubMed Web of Science ®Google Scholar
• Cairns AP, McMillan SA, Crockard AD et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann. Rheum. Dis.62, 272–273 (2003).
   PubMedGoogle Scholar
• Benucci M, Gobbi FL, Del Rosso A et al. Disease activity and antinucleosome antibodies in systemic lupus erythematosus. Scand. J. Rheumatol.32, 42–45 (2003).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Adrianzen OA, Koutouzov S, Mota RM et al. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J. Rheumatol.33, 1538–1544 (2006).
   PubMedGoogle Scholar
• Sinico RA, Radice A, Ikehata M et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann. NY Acad. Sci.1050, 193–200 (2005).
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Lopez-Trascasa M, Potlukova E et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol. Dial. Transplant.21, 115–121 (2006).
   Google Scholar
• Moroni G, Trendelenburg M, Del Papa N et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis.37, 490–498 (2001).
   PubMed Web of Science ®Google Scholar
• Oelzner P, Deliyska B, Funfstuck R, Hein G, Hermann D, Stein G. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus – relationship with disease activity and renal involvement. Clin. Rheumatol.22, 271–278 (2003).
   PubMed Web of Science ®Google Scholar
• Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis.62, 556–560 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia CO, Molina JF, Gutierrez-Urena S et al. Autoantibody profile in African–American patients with lupus nephritis. Lupus5, 602–605 (1996).
   PubMedGoogle Scholar
• Tapanes FJ, Vasquez M, Ramirez R, Matheus C, Rodriguez MA, Bianco N. Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropathy: are anti-extractable nuclear antibodies protective? Lupus9, 437–444 (2000).
   PubMedGoogle Scholar
• Godfrey T, Cuadrado MJ, Fofi C et al. Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft–Gault formula for renal involvement in systemic lupus erythematosus patients. Rheumatology (Oxford)40, 324–328 (2001).
   PubMedGoogle Scholar
• Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol.16, 467–473 (2005).
   PubMed Web of Science ®Google Scholar
• Li Y, Tucci M, Narain S et al. Urinary biomarkers in lupus nephritis. Autoimmun. Rev.5, 383–388 (2006).
   PubMed Web of Science ®Google Scholar
• Pitashny M, Schwartz N, Qing X et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum.56, 1894–1903 (2007).
   PubMed Web of Science ®Google Scholar
• Egner W. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol.53, 424–432 (2000).
   PubMed Web of Science ®Google Scholar
• Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann. Rheum. Dis.52, 851–856 (1993).
   PubMed Web of Science ®Google Scholar
• Villalta D, Tozzoli R, Bizzaro N, Tonutti E, Ghirardello A, Doria A. The relevance of autoantigen source and cutoff definition in antichromatin (nucleosome) antibody immunoassays. Ann. NY Acad. Sci.1050, 176–184 (2005).
   PubMedGoogle Scholar
• Buliard A, Fortenfant F, Ghillani-Dalbin P, Musset L, Oksman F, Olsson NO. [Analysis of nine autoantibodies associated with systemic autoimmune diseases using the Luminex technology. Results of a multicenter study]. Ann. Biol. Clin. (Paris)63, 51–58 (2005).
   PubMedGoogle Scholar
• Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med.189, 1639–1648 (1999).
   PubMed Web of Science ®Google Scholar
• Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science279, 1052–1054 (1998).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Watanabe N, Akikusa B et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum.48, 486–494 (2003).
   PubMedGoogle Scholar
• Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest.59, 90–96 (1977).
   PubMed Web of Science ®Google Scholar
• Madaio MP, Carlson J, Cataldo J, Ucci A, Migliorini P, Pankewycz O. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J. Immunol.138, 2883–2889 (1987).
   PubMed Web of Science ®Google Scholar
• Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology (Oxford)40, 1405–1412 (2001).
   PubMedGoogle Scholar
• Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab. Invest.69, 494–507 (1993).
   PubMedGoogle Scholar
• Mason LJ, Lambrianides A, Haley JD et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res. Ther.7, R971–R983 (2005).
   Google Scholar
• Katz JB, Limpanasithikul W, Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med.180, 925–932 (1994).
   PubMed Web of Science ®Google Scholar
• Roberts JL, Wyatt RJ, Schwartz MM, Lewis EJ. Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis. Clin. Immunol. Immunopathol.29, 223–241 (1983).
   PubMedGoogle Scholar
• Esparza RH, Swaak T, Aarden L, Smeenk R. Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal. J. Rheumatol.12, 1109–1117 (1985).
   PubMedGoogle Scholar
• Pankewycz OG, Migliorini P, Madaio MP. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J. Immunol.139, 3287–3294 (1987).
   PubMed Web of Science ®Google Scholar
• Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus.14, 19–24 (2005).
   PubMed Web of Science ®Google Scholar
• Izui S, Lambert PH, Miescher PA. Failure to detect circulating DNA–anti-DNA complexes by four radioimmunological methods in patients with systemic lupus erythematosus. Clin. Exp. Immunol.30, 384–392 (1977).
   PubMed Web of Science ®Google Scholar
• Couser WG, Salant DJ. In situ immune complex formation and glomerular injury. Kidney Int.17, 1–13 (1980).
   PubMed Web of Science ®Google Scholar
• Burny W, Lebrun P, Cosyns JP, Saint-Remy JM. Treatment with dsDNA–anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice. Lupus6, 4–17 (1997).
   PubMedGoogle Scholar
• Sabbaga J, Line SR, Potocnjak P, Madaio MP. A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, the major non-collagenous protein component of the glomerular basement membrane. Eur. J. Immunol.19, 137–143 (1989).
   PubMed Web of Science ®Google Scholar
• Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Crossreactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest.77, 1824–1830 (1986).
   PubMed Web of Science ®Google Scholar
• Mostoslavsky G, Fischel R, Yachimovich N et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur. J. Immunol.31, 1221–1227 (2001).
   PubMed Web of Science ®Google Scholar
• Croquefer S, Renaudineau Y, Jousse S et al. The anti-α-actinin test completes anti-DNA determination in systemic lupus erythematosus. Ann. NY Acad. Sci.1050, 170–175 (2005).
   PubMedGoogle Scholar
• Becker-Merok A, Kalaaji M, Haugbro K et al. α-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res. Ther.8, R162 (2006).
   Google Scholar
• Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet.24, 251–256 (2000).
   PubMed Web of Science ®Google Scholar
• Kos CH, Le TC, Sinha S et al. Mice deficient in α-actinin-4 have severe glomerular disease. J. Clin. Invest.111, 1683–1690 (2003).
   PubMed Web of Science ®Google Scholar
• Deocharan B, Zhou Z, Antar K et al. α-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice. J. Immunol.179, 1313–1321 (2007).
   PubMed Web of Science ®Google Scholar
• Deocharan B, Qing X, Lichauco J, Putterman C. α-actinin is a crossreactive renal target for pathogenic anti-DNA antibodies. J. Immunol.168, 3072–3078 (2002).
   PubMed Web of Science ®Google Scholar
• Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is α-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum.50, 866–870 (2004).
   PubMedGoogle Scholar
• Renaudineau Y, Croquefer S, Jousse S et al. Association of α-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum.54, 2523–2532 (2006).
   PubMedGoogle Scholar
• Zhao Z, Deocharan B, Scherer PE, Ozelius LJ, Putterman C. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of α-actinin. J. Immunol.176, 7704–7714 (2006).
   PubMedGoogle Scholar
• Greene DK, Tumova S, Couchman JR, Woods A. Syndecan-4 associates with α-actinin. J. Biol. Chem.278, 7617–7623 (2003).
   PubMed Web of Science ®Google Scholar
• Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum.42, 833–843 (1999).
   PubMedGoogle Scholar
• Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J. Autoimmun.22, 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology43, 220–224 (2004).
   PubMedGoogle Scholar
• Laderach D, Koutouzov S, Bach JF, Yamamoto AM. Concomitant early appearance of anti-ribonucleoprotein and anti-nucleosome antibodies in lupus prone mice. J. Autoimmun.20, 161–170 (2003).
   PubMedGoogle Scholar
• Kramers C, Hylkema MN, van Bruggen MC et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J. Clin. Invest.94, 568–577 (1994).
   PubMed Web of Science ®Google Scholar
• Berden JH, Licht R, van Bruggen MC, Tax WJ. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr. Opin. Nephrol. Hypertens.8, 299–306 (1999).
   PubMedGoogle Scholar
• van Bruggen MC, Kramers C, Walgreen B et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol. Dial. Transplant.12, 57–66 (1997).
   PubMedGoogle Scholar
• Berden JH, Grootscholten C, Jurgen WC, van der Vlag J. Lupus nephritis: a nucleosome waste disposal defect? J. Nephrol.15(Suppl. 6), S1–S10 (2002).
   PubMedGoogle Scholar
• Kalaaji M, Fenton KA, Mortensen ES et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int.71, 664–672 (2007).
   PubMed Web of Science ®Google Scholar
• Madaio MP, Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J. Autoimmun.11, 535–538 (1998).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature271, 67–69 (1978).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L. Broken dogma: penetration of autoantibodies into living cells. Immunol. Today17, 163–164 (1996).
   PubMedGoogle Scholar
• Deng SX, Hanson E, Sanz I. In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies. Int. Immunol.12, 415–423 (2000).
   PubMed Web of Science ®Google Scholar
• Yanase K, Madaio MP. Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J. Autoimmun.24(2), 145–151 (2005).
   PubMedGoogle Scholar
• Yu CL, Huang MH, Tsai CY et al. The effect of human polyclonal anti-dsDNA autoantibodies on apoptotic gene expression in cultured rat glomerular mesangial cells. Scand. J. Rheumatol.27, 54–60 (1998).
   PubMed Web of Science ®Google Scholar
• Hsieh SC, Sun KH, Tsai CY et al. Monoclonal antidouble stranded DNA antibody is a leucocyte-binding protein to up-regulate interleukin-8 gene expression and elicit apoptosis of normal human polymorphonuclear neutrophils. Rheumatology40, 851–858 (2001).
   PubMed Web of Science ®Google Scholar
• Kubota T, Watanabe N, Kanai Y, Stollar BD. Enhancement of oxidative cleavage of DNA by the binding sites of two anti-double-stranded DNA antibodies. J. Biol. Chem.271, 6555–6561 (1996).
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JC, Lai KB, Wong KC, Lai CK. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clin. Immunol. Immunopathol.81, 229–238 (1996).
   PubMedGoogle Scholar
• Lai KN, Leung JC, Lai KB, Lai CK. Effect of anti-DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor-β, and nitric oxide synthase in cultured endothelial cells. Scand. J. Rheumatol.26, 461–467 (1997).
   Google Scholar
• Lai KN, Leung JC, Lai KB, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J. Pathol.178, 451–457 (1996).
   PubMed Web of Science ®Google Scholar
• Antes U, Heinz HP, Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum.31, 457–464 (1988).
   PubMed Web of Science ®Google Scholar
• Wener MH, Uwatoko S, Mannik M. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum.32, 544–551 (1989).
   PubMed Web of Science ®Google Scholar
• Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol. Immunol.44, 2147–2151 (2007).
   PubMedGoogle Scholar
• Trouw LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest.114, 679–688 (2004).
   PubMed Web of Science ®Google Scholar
• Sangle SR, D'Cruz DP, Jan W et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann. Rheum. Dis.62, 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Nochy D, Daugas E, Droz D et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J. Am. Soc. Nephrol.10, 507–518 (1999).
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum.50, 2569–2579 (2004).
   PubMedGoogle Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4, 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Noël LH, Zuber J et al.The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am. J. Kidney Dis.41, 1205–1211 (2003).
   PubMedGoogle Scholar
• Bhandari S, Harnden P, Brownjohn AM, Turney JH. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM91, 401–409 (1998).
   PubMed Web of Science ®Google Scholar
• Frampton G, Hicks J, Cameron JS. Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int.39, 1225–1231 (1991).
   PubMed Web of Science ®Google Scholar
• Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am. J. Kidney Dis.43, 28–36 (2004).
   PubMed Web of Science ®Google Scholar
• Fofi C, Cuadrado MJ, Godfrey T, Abbs I, Khamashta MA, Hughes GR. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin. Exp. Rheumatol.19, 75–77 (2001).
   PubMedGoogle Scholar
• Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation68, 241–246 (1999).
   PubMed Web of Science ®Google Scholar
• Vaidya S, Sellers R, Kimball P et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation69, 1348–1352 (2000).
   PubMedGoogle Scholar
• Forman JP, Lin J, Pascual M, Denton MD, Tolkoff-Rubin N. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am. J. Transplant.4, 1786–1791 (2004).
   PubMedGoogle Scholar